Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- Is It Time For a New Blood Pressure Treatment Goal?In 2017 the American College of Cardiology (ACC) and the American Heart Association (AHA) lowered the definition of hypertension to ≥130/80 mm Hg, whereas the 2023 European Society of Hypertension (ESH) and the 2024 European Society of Cardiology (ESC) guidelines use a definition of ≥140/90 mm Hg.
- ACC CardiaCast: Highlights from EuroPCR 2025In this inaugural episode of the new podcast series produced by ACC’s Interventional Member Section, Dr. Poonam Velagapudi is joined by featured guests Drs. Debabrata Dash and Thomas Cuisset to discuss the Highlights from EuroPCR 2025.
- ACC Health Equity Summit Focuses on Opportunities to Improve Health Care For AllThe ACC brought together leaders across cardiology, along with other critical stakeholders, for a Health Equity Summit on June 25 focused on building and sustaining adaptive and resilient health systems.
- DanGer Shock: Microaxial Flow Pump Beneficial in STEMI-CS Patients Undergoing Hemodynamic MonitoringThe microaxial flow pump (mAFP) unloads the heart in STEMI-cardiogenic shock (CS) patients undergoing hemodynamic monitoring with a pulmonary artery catheter (PAC) by reducing native cardiac output (CO), pulmonary pressures and left ventricular filling pressures...
- JACC: CardioOncology Expert Panel Recommends Equivalence Ratios For Some Chemotherapy Drugs Post Childhood CancerAmong anthracycline and anthraquinone agents, the risk of cancer therapy-related cardiac dysfunction (CTRCD) after treatment for childhood cancer is lower with daunorubicin and higher with mitoxantrone compared with doxorubicin...